MICHAEL SANTILLAN: Open Payments
NPI 1861139628 · MISSION VIEJO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$876 in 36 payments from 14 companies in 2025. Trend: 2023 $4,150 · 2024 $4,820 · 2025 $876
Food & beverage: $876
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $157 |
| Janssen Pharmaceuticals, Inc | 4 | $127 |
| Alkermes, Inc. | 4 | $95 |
| ABBVIE INC. | 5 | $85 |
| Supernus Pharmaceuticals, Inc. | 3 | $69 |
| E.R. Squibb & Sons, L.L.C. | 2 | $67 |
| Neurocrine BioSciences, Inc. | 2 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Lundbeck LLC | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
Products named: HETLIOZ, SPRAVATO, REXULTI, ARISTADA, VRAYLAR, COBENFY, INGREZZA, CAPLYTA.
Industry payments across CA — which companies pay providers there.
